Clinics in New York, London, and Dubai promise to halt — even reverse — aging. Thousands worldwide already take off-label medications. How close are we really to a 200-year lifespan? The answer lies somewhere between the laboratory evidence and the commercial hype.
📖 Read more: Senolytic Drugs: Reversing Aging
The Longevity Industry: Numbers and Reality
The longevity clinic sector is booming. In the US alone, over 2,000 people are already taking rapamycin off-label, according to estimates from University of Wisconsin researchers (GeroScience, 2023). Telemedicine services have begun expanding access to these drugs, while longevity-focused platforms offer packages ranging from $500 to $25,000 annually.
The number of people over 65 is expected to reach 2 billion by 2050. In the US, Medicare expenditures alone exceed $1 trillion per year. This creates enormous economic incentive for therapies targeting biological aging rather than treating each disease separately.
Rapamycin: The Most Studied Anti-Aging Drug
If there is one drug that dominates the longevity conversation, it is rapamycin (sirolimus). Originally discovered on Rapa Nui (Easter Island) and FDA-approved for transplant rejection prevention, its mechanism works by inhibiting the protein kinase mTORC1 (mechanistic Target Of Rapamycin Complex 1), a key regulator of growth, metabolism, and aging.
Genetic inhibition of mTORC1 extends lifespan in yeast, worms, flies, and mice. In mammals, rapamycin enhances cognitive function by 25-100% in young mice, reverses age-related cardiac hypertrophy and diastolic dysfunction, The benefits lasted even after stopping treatment.
Key principle: Inhibiting mTORC1 is geroprotective, but “off-target” inhibition of the second complex mTORC2 — which happens with high daily doses — causes metabolic side effects like insulin resistance. Intermittent dosing (e.g. weekly) appears to avoid this problem.
What the Human Data Shows
A landmark survey published in May 2023 in GeroScience collected data from 333 adults taking rapamycin off-label and 172 who were not. The results defied expectations.
Users were 78% male, average age 61, and 77.7% took rapamycin under physician supervision. Median duration of use was 218 days. The only statistically significant side effect compared to non-users was mouth sores — a known and reversible effect.
Even more interesting: several side effects theoretically associated with rapamycin were significantly less common in users — abdominal cramps, depression, anxiety, and eye pain all occurred less frequently. Regarding COVID-19, continuous rapamycin users had 88.5% mild infections, zero severe cases, and zero long COVID — compared with non-users, where 46.3% had moderate symptoms, 3.7% severe, and 5.6% long COVID.
Clinical Trials Underway
More than 15 clinical trials are underway or launching soon at universities worldwide, according to a review published in October 2023 in GeroScience:
- PEARL (UCLA/AgelessRx): 150 participants, 5mg or 10mg rapamycin weekly for 12 months — primary endpoint is visceral fat change via DXA.
- EVERLAST (University of Wisconsin): 72 elderly adults with insulin resistance, everolimus 0.5mg/day or 5mg/week vs placebo for 24 weeks — studying metabolism, cognition, cardiac function, and muscle strength.
- REACH (UT San Antonio): 40 patients with mild cognitive impairment or early Alzheimer's, 1mg rapamycin daily for 12 months.
- VIBRANT (Columbia University): 50 women with premature ovarian insufficiency, 5mg weekly for 3 months — rapamycin extends ovarian lifespan in rodents.
📖 Read more: Cryonics: Will We Wake Up in the Future?
Beyond Rapamycin: Senolytics, NAD+ and Plasma
Rapamycin is not the only tool in the geroscience arsenal. Senolytics — drugs that destroy senescent cells — are in active clinical development. The dasatinib + quercetin combination continues to be studied in multiple clinical trials, while the NIA (National Institute on Aging) actively funds research into senolytic and senomorphic compounds.
NAD+ replenishment through NMN (nicotinamide mononucleotide) or NR (nicotinamide riboside) supplements is another popular approach. NAD+ levels naturally decline with age, and the idea behind these compounds is restoring cellular energy. Results from clinical trials remain mixed — some show increased blood NAD+ levels, but long-term clinical benefits have not been proven.
Plasma exchange and “young blood” infusions also generate interest, though the FDA has repeatedly warned against unapproved “young blood” therapies. The science behind parabiosis (connecting the circulatory systems of young and old animals) shows intriguing evidence in mice, but translation to humans requires far more data.
The ITP Program: Gold Standard in Research
The NIA's Interventions Testing Program (ITP) is perhaps the most rigorous anti-aging intervention testing program in existence. Operating since 2004 across three independent sites — Jackson Laboratory, University of Michigan, and UT Health San Antonio — it uses genetically heterogeneous UM-HET3 mice.
The program tests up to 6 peer-reviewed interventions annually. Rapamycin remains the most consistently effective compound tested — extending lifespan in both male and female mice even when administered late in life. Any researcher or organization can submit proposals for testing, with an annual deadline in February.
Science or Marketing?
This raises the key question. While laboratory data is promising, longevity clinics often sell false certainty. Packages exceeding $100,000 that include whole-body MRI scans, DNA methylation analyses, IV NAD+ therapy, and rapamycin prescriptions are marketed as “prevention” — but none have been proven to actually extend human life.
There are significant risks. At approved immunosuppressive doses, rapamycin causes dyslipidemia in 30-72% of patients, glucose intolerance in 22%, and increased risk of new-onset diabetes (HR 1.36-1.9). Lower weekly doses show much better safety profiles, but data remains limited.
The 333-user survey, while encouraging, was self-reported with no blinded control group. The population was self-selected — people who exercise regularly (89.6%), eat healthily (97.3%), and practice intermittent fasting (70.4%). They represent a “health elite” that may feel well regardless of rapamycin.
What It Means in Practice
A 200-year lifespan remains science fiction. But extending healthspan — years of healthy life — could become reality in the coming decades. Rapamycin, senolytics, and other interventions may ultimately delay multiple age-related diseases simultaneously rather than fighting them one by one.
Until then, the reality is simpler: regular exercise, balanced diet, adequate sleep, and routine medical checkups remain the most evidence-based longevity strategies. And they cost considerably less than $25,000 per year.